GYRE GYRE THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1124105 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.4%
TTM net income YoY-801.1%
TTM EPS YoY-2,500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin94.1%
Operating margin-20.6%
Net margin-30.1%
FCF margin-20.3%
EBITDA margin-18.8%
Returns
ROE-34.9%
ROA-20.3%
ROIC (approx.)-31.0%
Asset turnover0.68x
Leverage & solvency
Liabilities / assets17.5%
Debt / equity0.00x
Current ratio4.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.63x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $116.59M | $105.76M |
| Cost of revenue | $5.42M | $3.88M |
| Gross profit | $111.17M | $101.87M |
| R&D expense | $13.70M | $12.02M |
| SG&A expense | $20.80M | $16.11M |
| Operating income | $11.49M | $16.16M |
| Pretax income | $14.44M | $23.22M |
| Income tax | $4.56M | $5.32M |
| Net income | $9.88M | $17.90M |
| EBITDA | $13.97M | $17.71M |
| EPS (basic) | 0.06 | 0.14 |
| EPS (diluted) | 0.02 | 0.05 |
| Weighted avg. shares (diluted) | 103.18M | 102.29M |
| Banking | ||
| Net interest income | $1.75M | $1.55M |
| Balance sheet | ||
| Cash & equivalents | $49.19M | $11.81M |
| Short-term investments | $15.36M | $14.86M |
| Receivables | $31.08M | $19.59M |
| Inventory | $10.17M | $6.34M |
| Current assets | $149.36M | $64.79M |
| PP&E, net | $27.55M | $23.88M |
| Intangibles | $4.73M | $273,000 |
| Total assets | $219.76M | $125.41M |
| Current liabilities | $23.78M | $19.52M |
| Total liabilities | $31.40M | $27.00M |
| Shareholders' equity | $62.50M | $63.32M |
| Shares outstanding | 91.31M | 86.31M |
| Cash flow statement | ||
| Operating cash flow | $1.01M | -$3.64M |
| Capital expenditure | $1.19M | $2.31M |
| Free cash flow | -$180,000 | -$5.96M |
| Investing cash flow | -$474,000 | -$19.88M |
| Financing cash flow | $24.38M | $2.10M |
| Depreciation & amortization | $2.48M | $1.55M |
| Stock-based compensation | $7.16M | $831,000 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.